Wülfing Pia, Kersting Christian, Tio Joke, Fischer Rudolph-Josef, Wülfing Christian, Poremba Christopher, Diallo Raihanatou, Böcker Werner, Kiesel Ludwig
Department of Obstetrics and Gynecology, University of Münster, Muenster, Germany.
Clin Cancer Res. 2004 Apr 1;10(7):2393-400. doi: 10.1158/1078-0432.ccr-03-0115.
Endothelin-1 (ET-1) and its receptors (ET(A)R and ET(B)R), referred to as the endothelin (ET) axis, are overexpressed in breast carcinomas, and influence tumorigenesis and tumor progression by various mechanisms, including angiogenesis. The objective of the study was to clarify if expression of the ET axis participates in angiogenesis of breast carcinoma
We analyzed expression of ET-1, ET(A)R, ET(B)R, and vascular endothelial growth factor (VEGF) immunohistochemically in 600 tissue array specimens from 200 paraffin-embedded breast carcinomas performing tissue microarray technology. Microvessel density (MVD) was determined by counting microvessels (identified by factor VIII) in each core specimen.
Moderate or strong immunostaining was observed for ET-1 in 25.4%, for ET(A)R in 43.7%, and for ET(B)R in 22.2% of breast carcinomas. Of all cases, 44.7% showed significant expression of VEGF. MVD varied between different tumor specimens (range, 0-80; median, 17). We observed a statistically significant correlation between MVD and ET expression status with higher MVD in ET-positive tumors. Moreover, expression of VEGF was found more frequently in tumors with overexpression of the ET axis (each P < 0.001). Staining of VEGF was correlated positively with MVD CONCLUSIONS: These results indicate that increased ET-1, ET(A)R, and ET(B)R expression is associated with increased VEGF expression and higher vascularity of breast carcinomas and, thus, could be involved in the regulation of angiogenesis in breast cancer. Our findings provide evidence that the expression pattern of the ET-axis and in particular of ET(A)R may have clinical relevance in future antiangiogenic targeted therapies for breast cancer.
内皮素-1(ET-1)及其受体(ET(A)R和ET(B)R),即内皮素(ET)轴,在乳腺癌中过度表达,并通过多种机制影响肿瘤发生和肿瘤进展,包括血管生成。本研究的目的是阐明ET轴的表达是否参与乳腺癌的血管生成。
我们采用组织芯片技术,对来自200例石蜡包埋乳腺癌的600个组织芯片标本进行免疫组织化学分析,检测ET-1、ET(A)R、ET(B)R和血管内皮生长因子(VEGF)的表达。通过计数每个核心标本中的微血管(由因子VIII识别)来确定微血管密度(MVD)。
在25.4%的乳腺癌中观察到ET-1呈中度或强免疫染色,43.7%的病例中ET(A)R呈阳性,22.2%的病例中ET(B)R呈阳性。在所有病例中,44.7%显示VEGF有显著表达。不同肿瘤标本的MVD各不相同(范围为0 - 80;中位数为17)。我们观察到MVD与ET表达状态之间存在统计学显著相关性,ET阳性肿瘤中的MVD更高。此外,在ET轴过表达的肿瘤中更频繁地发现VEGF表达(各P < 0.001)。VEGF染色与MVD呈正相关。结论:这些结果表明,ET-1、ET(A)R和ET(B)R表达增加与乳腺癌中VEGF表达增加和血管生成增加相关,因此可能参与乳腺癌血管生成的调节。我们的研究结果提供了证据,表明ET轴尤其是ET(A)R的表达模式在未来乳腺癌抗血管生成靶向治疗中可能具有临床相关性。